Theravance Biopharma, Inc. - Ordinary Shares (TBPH): Price and Financial Metrics
TBPH Price/Volume Stats
| Current price | $9.34 | 52-week high | $11.98 |
| Prev. close | $9.20 | 52-week low | $8.21 |
| Day low | $9.02 | Volume | 433,000 |
| Day high | $9.38 | Avg. volume | 385,033 |
| 50-day MA | $8.99 | Dividend yield | N/A |
| 200-day MA | $9.64 | Market Cap | 453.55M |
TBPH Stock Price Chart Interactive Chart >
Theravance Biopharma, Inc. - Ordinary Shares (TBPH) Company Bio
Theravance Biopharma, Inc. engages in the research and development activities focusing on the diseases of the lung and gastrointestinal tract, and infectious diseases, as well as on the acute care setting markets. The company was founded in 2013 and is based in George Town, the Cayman Islands.
Latest TBPH News From Around the Web
Below are the latest news stories about THERAVANCE BIOPHARMA INC that investors may wish to consider to help them evaluate TBPH as an investment opportunity.
7 Short-Squeeze Stocks That Are Screaming for SpeculationWhile the concept of short-squeeze stocks has been all the rage throughout most of the pandemic-disruption cycle, we may have been doing this all wrong. |
Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of DirectorsTheravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH) today announced the appointment to its Board of Directors of Jeremy Grant, who serves as a Special Advisor to Irenic Capital Management LP ("Irenic"). With the addition of Mr. Grant, Theravance has appointed four new directors to the Board since 2020. |
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare ConferenceTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that members of its management team including Rick E Winningham, CEO, and Aziz Sawaf, CFO, will hold investor meetings during the 42nd Annual J.P. Morgan Healthcare Conference, January 8-11, 2024, in San Francisco, CA. |
The past five years for Theravance Biopharma (NASDAQ:TBPH) investors has not been profitableGenerally speaking long term investing is the way to go. But no-one is immune from buying too high. Zooming in on an... |
Theravance Bio (TBPH) Up 2.5% Since Last Earnings Report: Can It Continue?Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
TBPH Price Returns
| 1-mo | 4.24% |
| 3-mo | -1.37% |
| 6-mo | 2.64% |
| 1-year | -19.20% |
| 3-year | -58.41% |
| 5-year | -59.32% |
| YTD | -16.90% |
| 2023 | 0.18% |
| 2022 | 1.54% |
| 2021 | -37.82% |
| 2020 | -31.36% |
| 2019 | 1.17% |
Continue Researching TBPH
Here are a few links from around the web to help you further your research on Theravance Biopharma Inc's stock as an investment opportunity:Theravance Biopharma Inc (TBPH) Stock Price | Nasdaq
Theravance Biopharma Inc (TBPH) Stock Quote, History and News - Yahoo Finance
Theravance Biopharma Inc (TBPH) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...